Treatment strategies

Treatment in seroconversion maintains HIV specific immune responses similar to long term slow progressors

Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials

DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching

Lopinavir/r monotherapy used as second-line therapy in resource-limited settings

Dose optimisation: 50 mg ritonavir-boosting, 3TC dosing and raltegravir once-daily

Switching boosted-PIs to raltegravir

Scaling up: what to do first?

Tablets more acceptable than syrups in the ARROW trial

Current or former injecting drug use is not related to earlier switch or discontinuation of HAART compared to non-IDU patients since 1999

HIV viraemia may explain increased risk of cardiovascular disease, death and other serious events in patients interrupting treatment in the SMART trial: new study to randomise patients with CD4 counts >500 to start immediate treatment or defer to <350 cells/mm3

CD4 increases in immunological non-responders despite suppressive therapy following switch to nuke-sparing regimen of ATZ/SQV/r

Autologous stem cells transplant (ASCT) in HIV-positive individuals with a relapsed non-Hodgkin’s lymphoma (NHL) or Hodgkin’s disease (HD)

Treatment interuption arm in DART trial is stopped early

Simplification to atazanavir/ritonavir monotherapy

Summary of STI studies: SMART shows clear increased risk from interrupting treatment at any CD4 count

Treatment in primary HIV infection

Therapeutic vaccinations and treatment interruptions

Improved clinical outcome in 80% patients who modified an NNRTI or PI dose following therapeutic drug monitoring (TDM)

Another chance for 3TC in patients with M184V mutation?

Kaletra monotherapy: small studies and early data

Interruption of treatment is safe for those who started too early

STIs in resource limited settings

Studies and strategies with existing drugs

Treatment interruption prior to five-drug regime shows no benefit at 48 weeks

Failure of alternating week-on and week-off therapy

Treatment interruption shows no benefit in drug-resistant HIV infection

Treatment interruption: a real choice

Nucleoside-sparing regimens

Lessons learned from early HAART in acute HIV infection

Gender differences in rates and reasons for stopping treatment

Immune reconstitution in older HIV-positive individuals

Treatment interruptions: cycles, pauses, are just plain stopping?

The advantages of fosamprenavir; comparing saquinavir/r to lopinavir/r; reducing viral load to <3 copies; AZT-d4T cross resistance; and rising HCV rates

Immunology and treatment interruption data presented at the 42nd ICAAC

Treatment interruptions may result in poor T-cell recovery in patients with nadir CD+ count <50 cells/mm3

Treatment interruptions are safe in patients with CD4+ count between 300 to 500 cells/mm3 and viral loads lower than 70,000 copies/mL

Treatment interruption strategy reports from the XIV International AIDS Conference

Aminoperazine shows promise in enhancing immune response of HIV patients

Interleukin-2 with dual nucleoside therapy

Immunotherapy at the 1st IAS conference

Outcome of patients with discordant responses to HAART

Preliminary data from four studies of double PI regimen using once daily Fortovase plus “mini dose” ritonavir

Interleukin-2 improves CD4+ cell counts in patients with poor immune response to HAART

Use of cytokines in HIV: colony-stimulating factors, erythropoietin, and interleukin-2

Structured treatment interruptions

Study shows immune system can control HIV: early antiviral treatment primes the immune system to suppress viral levels without drugs

Human IL-12 may augment HIV-specific immunity in HIV-positive patients

Structured treatment interruptions and treatment intensification

New developments in affordable antiretroviral therapy: intermittent treatment

Once-daily protease-based regimens

What is the significance of blips in viral load?

Phase III study of GM-CSF in advanced HIV disease

GM-CSF beneficial for patients with advanced HIV disease

French National Drug Agency re-commends use of IL-2 if HAART does not lead to an increase in CD4 count to greater than 200 cells/mm3

Post navigation